<DOC>
	<DOCNO>NCT02097056</DOCNO>
	<brief_summary>This multi-center , open-label , single-arm , prospective , phase IV trial , evaluate safety efficacy donepezil hydrochloride patient moderate severe Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy Donepezil HCl 23 mg Patients With Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description>This study consist pre-treatment treatment phase . Pre-treatment phase approximately 4 week include screen baseline process . In treatment phase , 190 subject receive Donepezil HCl 23 mg daily 24 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female age 45 90 year 2 . Patients eligible condition dementia diagnosis list DSMIV 3 . Diagnosed probable Alzheimer 's Disease patient accord NINCDSADRDA criterion 4 . At time screening , MMSE le equal 20 AND CDR great equal 2 OR GDS great equal 4 5 . Patients , take stable donepezil 10 mg 3 month longer start study ( screen visit ) , evaluate eligible take donepezil 23 mg investigator 6 . Patients receive medication AD AChE inhibitor least 3 month prior screen visit exclude donepezil hydrochloride ( However , concomitant use memantine allow take stable dose less equal approve dose range least 3 month prior screen ) 7 . Medicines cerebral activation Gingko Biloba allow take patient receive stable dose 3 month prior screen visit Exclusion Criteria 1 . Patients participate clinical trial 3 month prior screen visit 2 . Patients severe psychiatric disorder schizophrenia 3 . Patients neurological disorder AD affect subject 's cognition ability ass cognition</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
</DOC>